» Articles » PMID: 33414788

A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza

Abstract

Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen the cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 . To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccine a simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen.

Citing Articles

Human RP105 monoclonal antibody enhances antigen-specific antibody production in unique culture conditions.

Yamazaki T, Iwasaki K, Tomono S, Imai M, Miwa Y, Shizuku M iScience. 2024; 27(9):110649.

PMID: 39246445 PMC: 11380396. DOI: 10.1016/j.isci.2024.110649.


Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells.

Jiang G, Huang Z, Yuan Y, Tao K, Feng W J Hematol Oncol. 2021; 14(1):139.

PMID: 34488814 PMC: 8422775. DOI: 10.1186/s13045-021-01150-x.

References
1.
Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T . Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020; 18(1):131. PMC: 7079408. DOI: 10.1186/s12967-020-02289-w. View

2.
Chaplin J, Chappell C, Clark E . Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory. J Exp Med. 2013; 210(10):2135-46. PMC: 3782047. DOI: 10.1084/jem.20130188. View

3.
ONeill L . The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2001; 2000(44):re1. DOI: 10.1126/stke.442000re1. View

4.
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S . Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019; 18(1):155. PMC: 6833286. DOI: 10.1186/s12943-019-1091-2. View

5.
Lopes A, Vandermeulen G, Preat V . Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019; 38(1):146. PMC: 6449928. DOI: 10.1186/s13046-019-1154-7. View